Table 1.
Anti-tumoral effect of standard dose imatinib in GISTs in relation to the primary mutation of the tumor
| Tumor genomic profile | Anti-tumoral effect of standard dose IMAa | ||
|---|---|---|---|
| Adequate | Reduced | Poor | |
| Favorable mutations | |||
| KIT exon 11 [mutants except p.(L576P)] [14, 15] | X | ||
| KIT exon 13 [14] | X | ||
| PDGFRA exon 12 [14, 15] | X | ||
| PDGFRA exon 14 [16] | X | ||
| PDGFRA exon 18[mutants except p.(D842V)] [28] | X | ||
| Unfavorable mutations | |||
| KIT exon 9 [18] | X | ||
| Wild type [15, 48] | X | ||
| KIT exon 11 p.(L576P) [17] | X | ||
| KIT exon 17 [28, 29] | X | ||
| PDGFRA exon 18 p.(D842V) [16, 19, 28] | X | ||
GIST gastrointestinal stromal tumor, IMA imatinib
aStandard dose IMA = 400 mg daily